DeLong Mark Jeffrey 4

Accession 0001492422-26-000059

CIK 0001492422other

View on SEC.gov Company Profile

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 4:11 PM ET

Size

4.5 KB

Accession

0001492422-26-000059

Research Summary

AI-generated summary of this filing

Updated Jan 23, 2026

Apellis (APLS) Chief Business & Strategy Officer Mark DeLong Sells 3,371 Shares

What Happened
Mark Jeffrey DeLong, Chief Business & Strategy Officer at Apellis Pharmaceuticals (APLS), sold 3,371 shares on January 22, 2026, at $21.77 per share, for proceeds of $73,371. The filing (Form 4) reports the sale as an open market or private sale and is coded as a sale (S). This transaction was executed to cover tax withholding on Restricted Stock Units (RSUs) that vested on January 21, 2026, per the filing footnote.

Key Details

Transaction date: 2026-01-22; price: $21.77 per share; total proceeds: $73,371.
Report filed: 2026-01-23 (timely relative to the transaction date).
Shares owned after the transaction: not specified in this filing.
Footnote: sale was to satisfy tax withholding on RSUs released January 21, 2026. (Footnote F1)
Transaction type: Sale (S); reported as open market or private sale.

Context
Sales to cover tax withholding on vested RSUs are routine compensation-related transactions and do not necessarily signal the insider's view on company prospects. Purchases generally carry more weight for assessing insider sentiment; this filing documents a routine, tax-related disposition.